| Interview with Dr. Emil Lou leading first of its kind CRISPR-based clinical trial to treat solid tumours Clinical trials to assess the safety and medical benefit of CRISPR therapies are complex. This is not only because they explore a novel technology, but also because the handling of human subjects requires significant interdisciplinary coordination. In Minnesota, a trial on CRISPR-engineered immunotherapy for solid tumour cancers has opened as the first one of its kind. In this article, Dr. Emil Lou, who is leading the trial, talks us through some of the associated challenges. | |
